Dinutuximab beta (Qarziba®)

Assessment Status NCPE Assessment Process Complete
Drug Dinutuximab beta
Brand Qarziba®
Indication For the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.
Assessment Process
Rapid review commissioned 19/10/2017
Rapid review completed 23/11/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 29/11/2017
Pre-submission consultation with Applicant 06/02/2018
Full submission received from Applicant 11/07/2018
Preliminary review sent to Applicant 20/08/2018
NCPE assessment re-commenced 18/09/2018
Factual accuracy sent to Applicant 04/10/2018
NCPE assessment re-commenced 12/10/2018
NCPE assessment completed 18/10/2018
NCPE assessment outcome Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments* 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations; May 2019